Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

Neoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but in ER-positive/HER2-negative (luminal) is still controversial, although a survival benefit has recently been observed when a histological response by Symmans’ method type 0 or I is achieved. The 21-gene Oncotype DX Breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales Murillo, Serafin, Gasol Cudos, Ariadna, Veas Rodriguez, Joel, Canosa Morales, Carles, Melé Olivé, Jordi, Vilardell Villellas, Felip, Sanchez Guzman, Douglas Rene, Iglesias Martínez, Edelmiro, Salud Salvia, Antonieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900764/
https://www.ncbi.nlm.nih.gov/pubmed/33601299
http://dx.doi.org/10.1016/j.breast.2021.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900764/
https://www.ncbi.nlm.nih.gov/pubmed/33601299
http://dx.doi.org/10.1016/j.breast.2021.01.001

Ejemplares similares